Molecular radiotherapy developer Theragnostics has appointed to its board Dr. Dennis Langer and Dr. Ken Herrmann as nonexecutive directors.
Langer has served at both public and private biotechnology, pharmaceutical, and diagnostic, companies, including as CEO of Neose Technologies, president of Dr. Reddy's North American business, and senior vice president of research and development at GlaxoSmithKline. He currently serves as a director of Myriad Genetics' Whitehead Institute for Biomedical Research and Brooklyn ImmunoTherapeutics.
Herrmann is the chair of the department of nuclear medicine at Essen University Hospital in Germany. Previously a professor in the Ahmanson Translational Imaging Division of the University of California, Los Angeles' department of molecular and medical pharmacology, Herrmann has also served as vice chair of the department of nuclear medicine at Germany's WĂĽrzburg University. Currently, he is chair of the European Association of Nuclear Medicine's oncology and theragnostics committee as well as section editor of the Journal of Nuclear Medicine.
